Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
Dateline City:
KENILWORTH, N.J.
Opinion for KEYTRUDA Based on Efficacy and Safety Data in More than 1,500 Patients with Advanced Melanoma as Both First-Line Therapy and in those Previously Treated
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of KEYTRUDA® (pembrolizumab),
the company’s anti-PD-1 therapy, for the treatment of advanced
(unresectable or metastatic) melanoma, as both first-line therapy and in
previously treated patients.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cancer & Oncology | European Medicines Agency (EMA) | Melanoma | Merck | Pharmaceuticals | Skin Cancer